|
1
|
Waxman S and Anderson KC: History of the
development of arsenic derivatives in cancer therapy. Oncologist.
2(Suppl 6): 3–10. 2001. View Article : Google Scholar
|
|
2
|
Soignet SL, Maslak P, Wang ZG, Jhanwar S,
Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J,
Scheinberg DA, Pandolfi PP and Warrell RP: Complete remission after
treatment of acute promyelocytic leukemia with arsenic trioxide. N
Engl J Med. 339:1341–1348. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soignet SL, Frankel SR, Douer D, Tallman
MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA,
Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R and
Warrell RP: United States multicenter study of arsenic trioxide in
relapsed acute promyelocytic leukemia. J Clin Oncol. 19:3852–3860.
2001.PubMed/NCBI
|
|
4
|
Uslu R, Sanli UA, Sezgin C, Karabulut B,
Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated
cytotoxicity and apoptosis in prostate and ovarian carcinoma cell
lines. Clin Cancer Res. 6:4957–4964. 2000.
|
|
5
|
Zhang TC, Cao EH, Li JF, Ma W and Qin JF:
Induction of apoptosis and inhibition of human gastric cancer
MGC-803 cell growth by arsenic trioxide. Eur J Cancer.
35:1258–1263. 1999. View Article : Google Scholar
|
|
6
|
Ling YH, Jiang JD, Holland JF and
Perez-Soler R: Arsenic trioxide produces polymerization of
microtubules and mitotic arrest before apoptosis in human tumor
cell lines. Mol Pharmacol. 62:529–538. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miller WH, Schipper HM, Lee JS, Singer J
and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res.
62:3893–3903. 2002.PubMed/NCBI
|
|
8
|
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ,
Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang
P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY and Chen Z: In vitro
studies on cellular and molecular mechanisms of arsenic trioxide
(As2O3) in the treatment of acute
promyelocytic leukemia: As2O3 induces NB4
cell apoptosis with downregulation of Bcl-2 expression and
modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061.
1996.PubMed/NCBI
|
|
9
|
Hug N and Lingner J: Telomere length
homeostasis. Chromosoma. 115:413–425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chou WC, Hawkins AL, Barrett JF, Griffin
CA and Dang CV: Arsenic inhibition of telomerase transcription
leads to genetic instability. J Clin Invest. 108:1541–1547. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Litzow MR: Arsenic trioxide. Expert Opin
Pharmacother. 9:1773–1785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Phatak P, Dai F, Butler M, Nandakumar MP,
Gutierrez PL, Edelman MJ, Hendriks H and Burger AM: KML001
cytotoxic activity is associated with its binding to telomeric
sequences and telomere erosion in prostate cancer cells. Clin
Cancer Res. 14:4593–4602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Glienke W, Chow KU, Bauer N and Bergmann
L: Down-regulation of wt1 expression in leukemia cell lines as part
of apoptotic effect in arsenic treatment using two compounds. Leuk
Lymphoma. 47:1629–1638. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin JO, Song MG, Kim YN, Park JI and Kwak
JY: The mechanism of fucoidan-induced apoptosis in leukemic cells:
involvement of ERK1/2, JNK, glutathione, and nitric oxide. Mol
Carcinog. 49:771–782. 2010.PubMed/NCBI
|
|
15
|
Yoon JS, Won YW, Kim SJ, Oh SJ, Kim ES,
Kim BK, Cho CG, Choi JH, Park BB, Lee MH and Lee YY: Anti-leukemic
effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways.
Invest New Drugs. 30:2284–2293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vermes I, Haanen C, Steffens-Nakken H and
Reutelingsperger C: A novel assay for apoptosis. Flow cytometric
detection of phosphatidylserine expression on early apoptotic cells
using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
d’Adda di Fagagna F, Hande MP, Tong WM,
Roth D, Lansdorp PM, Wang ZQ and Jackson SP: Effects of DNA
nonhomologous end-joining factors on telomere length and
chromosomal stability in mammalian cells. Curr Biol. 11:1192–1196.
2001. View Article : Google Scholar
|
|
18
|
Cawthon RM: Telomere length measurement by
a novel monochrome multiplex quantitative PCR method. Nucleic Acids
Res. 37:e212009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blackburn EH: Telomere states and cell
fates. Nature. 408:53–56. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
d’Adda di Fagagna F, Reaper PM,
Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G,
Carter NP and Jackson SP: A DNA damage checkpoint response in
telomere-initiated senescence. Nature. 426:194–198. 2003.
View Article : Google Scholar
|
|
21
|
Phatak P, Cookson JC, Dai F, Smith V,
Gartenhaus RB, Stevens MF and Burger AM: Telomere uncapping by the
G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in
vitro and in vivo consistent with a cancer stem cell targeting
mechanism. Br J Cancer. 96:1223–1233. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dynlacht BD: Regulation of transcription
by proteins that control the cell cycle. Nature. 389:149–152. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Darnell JE, Kerr IM and Stark GR: Jak-STAT
pathways and transcriptional activation in response to IFNs and
other extracellular signaling proteins. Science. 264:1415–1421.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akira S: Functional roles of STAT family
proteins: lessons from knockout mice. Stem Cells. 17:138–146. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirano T, Ishihara K and Hibi M: Roles of
STAT3 in mediating the cell growth, differentiation and survival
signals relayed through the IL-6 family of cytokine receptors.
Oncogene. 19:2548–2556. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smithgall TE, Briggs SD, Schreiner S,
Lerner EC, Cheng H and Wilson MB: Control of myeloid
differentiation and survival by Stats. Oncogene. 19:2612–2618.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cross TG, Scheel-Toellner D, Henriquez NV,
Deacon E, Salmon M and Lord JM: Serine/threonine protein kinases
and apoptosis. Exp Cell Res. 256:34–41. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Willems L, Tamburini J, Chapuis N, Lacombe
C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in
cancer: new data on targeted therapies. Curr Oncol Rep. 14:129–138.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hidalgo M and Rowinsky EK: The
rapamycin-sensitive signal transduction pathway as a target for
cancer therapy. Oncogene. 19:6680–6686. 2000. View Article : Google Scholar
|
|
34
|
Ortega-Molina A and Serrano M: PTEN in
cancer, metabolism, and aging. Trends Endocrinol Metab. 24:184–189.
2013. View Article : Google Scholar
|
|
35
|
Sawyers CL: Rational therapeutic
intervention in cancer: kinases as drug targets. Curr Opin Genet
Dev. 12:111–115. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Janus A, Linke A, Cebula B, Robak T and
Smolewski P: Rapamycin, the mTOR kinase inhibitor, sensitizes acute
myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of
arabinozide cytarabine. Anticancer Drugs. 20:693–701. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baldwin AS: The NF-kappa B and I kappa B
proteins: new discoveries and insights. Annu Rev Immunol.
14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guttridge DC, Albanese C, Reuther JY,
Pestell RG and Baldwin AS: NF-kappaB controls cell growth and
differentiation through transcriptional regulation of cyclin D1.
Mol Cell Biol. 19:5785–5799. 1999.PubMed/NCBI
|
|
39
|
Hinz M, Krappmann D, Eichten A, Heder A,
Scheidereit C and Strauss M: NF-kappaB function in growth control:
regulation of cyclin D1 expression and G0/G1-to-S-phase transition.
Mol Cell Biol. 19:2690–2698. 1999.PubMed/NCBI
|
|
40
|
Zhang Y, Cao EH and Qin JF: Up-regulation
of telomere-binding TRF1, TRF2 related to reactive oxygen species
induced by As2O3 in MGC-803 cells. Eur J
Pharmacol. 516:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
